Trial reportCancer prevention research (Philadelphia, Pa.)2015
Isoflavone pharmacokinetics and metabolism after consumption of a standardized soy and soy-almond bread in men with asymptomatic prostate cancer.
Trial report in Cancer prevention research (Philadelphia, Pa.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Tomato-Soy Juice Reduces Inflammation and Modulates the Urinary Metabolome in Adults With Obesity.Molecular nutrition & food research · 2026Trial
- Attitudes and adherence to changes in nutrition and physical activity following surgery for prostate cancer: a qualitative study.BMJ open · 2022Trial
- Impact of 18-Month Soy Protein Supplementation on Steroid Hormones and Serum Biomarkers of Angiogenesis, Apoptosis, and the Growth Hormone/IGF-1 Axis: Results of a Randomized, Placebo-Controlled Trial in Males Following Prostatectomy.Nutrition and cancer · 2022Trial
- Reduction of inflammation in chronic pancreatitis using a soy bread intervention: A feasibility study.Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2020Trial
- Consumption of soy isoflavone enriched bread in men with prostate cancer is associated with reduced proinflammatory cytokines and immunosuppressive cells.Cancer prevention research (Philadelphia, Pa.) · 2015Trial
- Botanical sources, biopharmaceutical profile, anticancer effects with mechanistic insight, toxicological and clinical evidence of prunetin: a literature review.Medical oncology (Northwood, London, England) · 2025Review
- Sustainable Extraction Technology of Fruit and Vegetable Residues as Novel Food Ingredients.Foods (Basel, Switzerland) · 2025Review
- Effects of Soy Bread on Cardiovascular Risk Factor, Inflammation and Oxidative Stress in Women With Active Rheumatoid Arthritis: A Randomized Double-Blind Controlled Trial.Clinical nutrition research · 2024Article
- Isoflavones Mediate Dendritogenesis Mainly through Estrogen Receptor α.International journal of molecular sciences · 2023Article
- Short-Term Soy Bread Intervention Leads to a Dose-Response Increase in Urinary Isoflavone Metabolites and Satiety in Chronic Pancreatitis.Foods (Basel, Switzerland) · 2023Article
- Anti-prostate cancer protection and therapy in the framework of predictive, preventive and personalised medicine - comprehensive effects of phytochemicals in primary, secondary and tertiary care.The EPMA journal · 2022Review
- Soy-tomato enriched diet reduces inflammation and disease severity in a pre-clinical model of chronic pancreatitis.Scientific reports · 2020Article
- Dietary Flavonoids for Immunoregulation and Cancer: Food Design for Targeting Disease.Antioxidants (Basel, Switzerland) · 2019Review
- Soy isoflavones and their metabolites modulate cytokine-induced natural killer cell function.Scientific reports · 2019Article
- A Novel Tomato-Soy Juice Induces a Dose-Response Increase in Urinary and Plasma Phytochemical Biomarkers in Men with Prostate Cancer.The Journal of nutrition · 2019Article
- Dietary Carcinogens and DNA Adducts in Prostate Cancer.Advances in experimental medicine and biology · 2019Review
- Pharmacokinetic Properties of Saffron and its Active Components.European journal of drug metabolism and pharmacokinetics · 2018Review
- Nutraceuticals in prostate cancer therapeutic strategies and their neo-adjuvant use in diverse populations.NPJ precision oncology · 2018Review
- Food-based natural products for cancer management: Is the whole greater than the sum of the parts?Seminars in cancer biology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Epidemiologic associations suggest that populations consuming substantial amounts of dietary soy exhibit a lower risk of prostate cancer. A 20-week randomized, phase II, crossover trial was conducted in 32 men with asymptomatic prostate cancer. The crossover involved 8 weeks each of soy bread (SB) and soy-almond bread (SAB). The primary objective was to investigate isoflavone bioavailability and metabolite profile. Secondary objectives include safety, compliance, and assessment of biomarkers linked to prostate carcinogenesis. Two distinct SBs were formulated to deliver approximately 60 mg aglycone equivalents of isoflavones per day. The isoflavones were present as aglycones (∼78% as aglycones) in the SAB whereas in the standard SB predominantly as glucosides (18% total isoflavones as aglycones). Compliance to SB (97% ± 4%) and SAB (92% ± 18%) was excellent; toxicity was rare and limited to grade 1 gastrointestinal complaints. Pharmacokinetic studies between SB and SAB showed modest differences. Peak serum concentration time (Tmax) was significantly faster with SAB meal compared with SB in some isoflavonoids, and AUC0 to 24 h of dihydrodaidzein and O-desmethylangolensin was significantly greater after an SB meal. An exploratory cluster analysis was used to identify four isoflavone-metabolizing phenotypes. Insulin-like growth factor-binding protein increased significantly by 41% (P = 0.024) with soy intervention. Findings from this study provide the necessary framework to study isoflavone-metabolizing phenotypes as a strategy for identification of individuals that might benefit or show resistance to cancer preventive strategies using dietary soy. A standardized SB used for future large-scale randomized clinical trials to affect human prostate carcinogenesis is feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.